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The bacterial transcription elongation factor NusG stimu-
lates the Rho-dependent transcription termination through a
direct interaction with Rho. The mechanistic basis of NusG
dependence of the Rho function is not known.Here, we describe
Rho* mutants I168V, R221C/A, and P235H that do not require
NusG for their termination function. These Rho* mutants have
acquired new properties, which otherwise would have been
imparted by NusG. A detailed analyses revealed that they have
more stable interactions at the secondary RNA binding sites of
Rho, which reduced the lag in initiating its ATPase as well as the
translocase activities. Thesemore stable interactions arose from
the significant spatial re-orientations of the P, Q, and R struc-
tural loops of the Rho central channel. We propose that NusG
imparts similar conformational changes in the central channel
of Rho, yielding faster isomerization of the open to the closed
hexameric states of the latter during its RNA-loading step. This
acceleration stabilizes the Rho-RNA interactions at many ter-
minators having suboptimal rut sites, thus making Rho-NusG
interactions so essential in vivo. Finally, identification of the
NusG binding sites on the Rho hexamer led us to conclude that
the former exerts its effect allosterically.
At the end of a significant number of operons in Escherichia
coli, DNA sequences do not code for intrinsic termination sig-
nals, characterized by a hairpin and a U-stretch (1). Transcrip-
tion termination factor Rho, a homo-hexameric RNA-depen-
dent ATPase, induces termination in these operons. Rho loads
onto unstructured C-rich RNA sequences (rut sites, the Rho-
utilization sites) and is capable of translocating along the RNA
using its RNA-dependent ATPase activity, and eventually dis-
lodges the elongating RNA polymerase (RNAP)3 (1, 2). By vir-
tue of these properties of Rho, long stretches of untranslated
RNA sequences are its ideal targets. Transcription on these
stretches can face premature termination byRho,which usually
happens in the cases of transcription-translation uncoupling.
Recent genomics study has revealed that Rho-dependent termi-
nation iswidespread in vivo, which could be themain reason for
its essentiality (3–6).
NusG, a transcription elongation factor, being bound to the
elongation complex (EC) through its N-terminal domain
(NTD) helps the latter to overcome the pauses by increasing the
elongation rate (5, 7, 8). Its C-terminal domain (CTD) is capable
of interacting with the Rho (9). This interaction stimulates the
Rho-dependent termination process in vitro, which is mani-
fested as early termination (10, 11). More recent studies indi-
cated that NusG is essential for recruiting Rho on a subset of
terminators in vivo (4, 6).Mechanism of stimulation of Rho-de-
pendent termination by NusG in vitro as well as the molecular
basis of NusG dependence of Rho to utilize a subset of termi-
nators in vivo is not known, knowledge of which is essential to
understand the intricacies of this transcription termination
process.
In this study, by screening a library of randomlymutagenized
rho, we have isolated Rho mutants, I168V, R221C, R221A, and
P235H (the Rho* mutants) that function independent of NusG
both in vivo and in vitro, and also suppress the defects of NusG
mutants defective for binding to Rho. These Rho mutants have
acquired the properties, which otherwise would have been
imparted by NusG. A detailed analyses revealed that they have
more stable interactions at the secondary RNAbinding channel
of Rho, which reduced the lag in initiating the ATPase activity
as well as increased the rate of hydrolysis. This more stable
interaction arose from significant conformational changes in
the R- andQ-loops of the Rho central channel.We propose that
interaction of NusG with Rho induces faster isomerization of
the open to the closed hexameric states of the latter. This in
turn stabilizes Rho-RNA interactions at the “weaker” termina-
tors having suboptimal rut sites, thus making Rho-NusG inter-
action essential in vivo. Finally, we have delineated that a hydro-
phobic patch encompassing residues 203–205 of Rho, located
away from the central channel is the functional interaction
site(s) for the NusG-CTD. Hence, we concluded that NusG
exerts its effect allosterically to the secondary RNA binding
sites of Rho.
Results
Rationale—To understand the mechanism of the NusG-me-
diated stimulation of the Rho-dependent termination process,
it is important to understand the NusG-induced conforma-
tional changes in the Rho molecule as well as the step(s) of the
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termination process influenced by it. Direct measurements of
these conformational changes in vitro may not be simple
because of the following reasons. NusG-CTD has six binding
sites on a Rho hexamer, one on each protomers. However, the
stoichiometry of this binding is, Rho hexamer::NusGmonomer
(12), whichmeans that at a given timeNusG occupies one of six
binding sites of the Rho. This poses a problem for in vitro detec-
tion of anyNusG-mediated conformational changes in the Rho,
as the majority of the sites remain unoccupied in a Rho-NusG
complex. Moreover, the NusG effect on Rho should be studied
in the context of a transcription EC,whereNusG-NTD remains
bound to RNAP and the CTD interacts with the nascent RNA-
bound Rho. Reconstitution of this set-up in vitro is technically
quite challenging. To overcome these problems, we decided to
genetically screen Rho mutants, which are capable of function-
ing independent of NusG. It is expected that such Rhomutants
will acquire certain properties as well as conformational
changes that otherwise would have been imparted by NusG.
Characterization of these Rhomutants for their functions (both
in vivo and in vitro) and their conformational changes would
elucidate the mechanism of the NusG action.
Screening and Isolation of RhoMutants That Function Indepen-
dently of NusG—Overexpression of NusG-NTD fragments in
vivo titrates out the full-length NusG (Fig. 1A) (13) and occu-
pies the majority of the ECs. Under this condition, due to the
absence of theNusG-CTDdomain, Rho-NusG interaction does
not occur and the termination process becomes inefficient,
which leads to toxicity (Fig. 1A, 0.2% arabinose panel). This
toxicity may also arise from the NusG-NTD induced alteration
in the transcription-translation coupling, if any. An MG1655
rac (RS862) strain, having a plasmid overexpressing NusG-
NTD from the arabinose-controlled PBAD promoter, was elec-
troporated with amutagenized plasmid library carrying the rho
(pHYD567). The transformants that grew in the presence of
0.2% arabinose (an overexpressing condition of NusG-NTD
fragment) contain the Rho mutants, which are capable of func-
tioning efficiently in the absence of bona fide Rho-NusG-CTD
interactions. These mutations were confirmed by sequencing.
We obtained two Rho mutants: I168V and R221C. We also
constructed R221A to see the effect of the amino acid change.
Previously, some Rho mutants were reported that displayed
enhanced as well as early termination activities (14, 15). From
that group, we chose the mutants P103L and P235H as their
altered properties weremost prominent.We tested them in our
assays as we envisioned that thesemay possess some properties
that are imparted byNusG.We termed all these Rhomutants as
Rho*.
In Vivo Functions of the Rho*Mutants—Deletion of chromo-
somal nusG by P1 transduction (Fig. 1B, left most panel) or the
expression of NusG-CTD mutants defective for Rho-binding
(G146D and L158Q expressed from pHYD3011 plasmid; Fig.
1C; see Ref. 9; Fig. 1B, top most panel), cause severe growth
defects toMG1655 strains expressingWTRho from a low-copy
pCL1920plasmid (RS862, chromosomal rho is deleted). At first,
we checked whether these Rho* mutants were capable of over-
coming the growth defects caused by the deletion of nusG (Fig.
1B) or by its mutations in the CTD (Fig. 1D). When the strains
(lacks the chromosomal copy of rho) expressing Rho* mutants
from a pCL1920 plasmidweremadenusG by P1 transduction,
healthy transductants were obtained (Fig. 1, B and D, Rho*
mutant panels) in all the cases except for the P103LRhomutant
(Fig. 1B, right most panel). This indicates that all the Rho*
mutants, except P103L, are capable of suppressing the growth
defects caused either due to the deletion of nusG or by the
presence of NusG mutants, G146D and L158Q. We did not
include P103L mutant in our subsequent experiments.
We have earlier identified and characterized a Rho-depen-
dent terminator, trac, in the rac prophage region that is highly
dependent on NusG in vivo (Fig. 2A) (6). When this terminator
was fused upstream of the lacZ reporter, a huge enhancement
of the-galactosidase activities was observed in the presence of
NusG-CTD mutants compared with that obtained for the
canonical TR1 terminator (TR1-lacZ) (6), which proved the
NusG dependence of this terminator. We used the trac-lacZ
reporter to assess the Rho* mutants-mediated suppression of
the termination read-through due to the presence of NusG-
CTD mutants. We used strain RS1430 having the trac-lacZ
reporter inserted into the chromosome. Each of the Rho*
and the NusG mutants were supplied from pCL1920 and
pHYD3011 plasmids, respectively. Compared with WT Rho,
the -galactosidase activities were significantly reduced in the
presence of different Rho* mutants. I168V exerted the best
effect and R221A was least effective (Fig. 2B). Therefore, the
Rho*mutants exertedmoderate to high levels of suppression of
the termination defects caused by NusG-CTD mutants. The
above results strongly indicated that these Rho* mutants are
capable of suppressing the growth and transcription termina-
tion defects that occurred due to the lack of Rho-NusG inter-
action, and hence these Rho mutants are less dependent on or
function independently of NusG in vivo.
In Vitro Properties of the RhoMutants—Next we assayed dif-
ferent properties of the purified Rho* mutants to understand
the step(s) in Rho-dependent termination affected by them. As
they efficiently suppressed the Rho binding as well as Rho-de-
pendent termination defects caused by theNusGmutants or its
deletion, we hypothesized that these Rho mutants might have
acquired unique properties. These properties would have been
imparted by NusG upon binding to Rho during the process of
transcription elongation.
At first, we performed in vitro transcription termination
assays using templates having either the H-19B tR1 terminator
(16) or the trac (6) terminator. The latter is more NusG-depen-
dent (6). Transcription was initiated from the PRM promoter
that naturally occurs before the trac termination region (Figs.
2A and 3A), whereas the initiation was from the strong T7A1
promoter for the template having the H-19B tR1 terminator.
When the T7A1 promoter was present, we performed single-
round transcription assays in the presence of rifampicin,
whereas for the weak promoter, PRM, multiple round transcrip-
tion was employed. The termination events were initiated by
adding either WT or Rho* mutants, both in the absence and
presence of WT NusG.
WT Rho produced two distinct termination zones both in
the presence and absence of NusG at theH-19BTR1 terminator
that is consistentwith the previous report (16). UnlikeWTRho,
the Rho* mutants tested in these assays exhibited early termi-
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nation even in the absence of NusG (Fig. 3A). I168V induced
less early termination compared with the others. The presence
ofmore inactive protein fractions (data not shown) could be the
reason for the less robust termination property of I168V Rho.
However, more transcripts were observed in the early termina-
tion zone when NusG was present. In case of the PRM-trac tem-
FIGURE 1. Growth characteristics of the Rho* mutants. A, screening strategies for isolating Rho mutants that can function in the absence of NusG. The
Rho-dependent transcription termination requires the interaction of Rho and NusG-CTD (9), absence of which leads to termination read-through and cell
death. The NTD of NusG has more affinity for the RNAP than the full-length NusG (13). So, its overexpression replaces the latter from the elongation complex
leading to conditional toxicity of the cells. Schematics show the representation of the toxicity of the overexpressed NusG-NTD in the presence of WT Rho. It is
expected that the Rhomutants, which can overcome this NusG-NTDmediated toxicity, do not require interactionwith NusG implying that they can terminate
in the absence of NusG. In the screening protocol, NTD of NusG was cloned under a pBAD promoter and was overexpressed with 0.2% arabinose (see the
picture of the growth plate). B, transductants obtained following the deletion of chromosomal nusG by P1 transduction of a MG1655racrho strain. In these
strains, WT and Rho* mutants (R221C, I168V, P235H) are expressed from pCL1920 plasmids as indicated. Effect of Rho P103L is shown for comparison. Plates
were incubated for 20 h at 37 °C. C, homology model of E. coli NusG depicting the Rho binding and termination defective mutations. D, transductants
obtained after removing the chromosomal nusG by P1 transduction of MG1655racrho strains that express different combinations of Rho and NusG
derivatives expressed from pCL1920 and pHYD3011 plasmids, respectively, as indicated. These NusG mutants are defective for Rho binding (9).
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plate, reactions were performed using a linearized DNA tem-
plate immobilized to streptavidin-coated magnetic beads so
that the amounts of released RNA could be measured in the
solution (Fig. 3B). Following the transcription reactions, super-
natant (S) and pellet (S  P) fractions were loaded separately.
We observed that WT Rho induced two distinct termination
zones in the absence (400–700 nt) and presence (300–400
nt) of NusG. This early termination in the presence of NusG is
similar to some other Rho-dependent terminators (10, 11) (Fig.
3A). In this case also, unlike theWTRho, early termination was
observed by the Rho* mutants even in the absence of NusG. In
these cases,many early terminated transcripts were observed in
the 300–400-nt zone similar to that observed when NusG was
present together with theWTRho. However, in the presence of
NusG more transcripts were observed in the 300–400-nt
termination zones of these Rho* mutants. Therefore, Rho*
mutants mimic the presence of NusG in the above reactions.
However, they are still capable of responding to NusG.
Earlier, induction of early termination by NusG was inter-
preted as the rate of increase in RNA release by Rho (10), and it
was later confirmed by us by measuring the release of RNA
from stalled EC (11). We hypothesized that the Rho* mutants
would accelerate the rate of RNA release in the absence of
NusG. We have used a DNA template having a trac terminator,
and a lac-operator sequence that is fused downstream of the
terminator (Fig. 3C). Earlier we have shown that at this termi-
nator, the rate and the efficiency of RNA release is highly de-
pendent on the presence of NusG (6), which was interpreted as
slow and less efficient formation of the translocase competent
Rhomolecule due to the presence of suboptimal rut sequences.
FIGURE 2. In vivo termination assays with the Rho*mutants. A, sequence of the PRM-trac-racR region of the rac prophage fused upstream of a lacZ cassette.
Different regions along with primers used for making the DNA templates are indicated. The transcription start site G, is shown as a small arrow. Promoter and
racR regions are highlighted. B, bar diagrams showing the-galactosidase activities indicating the termination efficiencies ofWT and Rho*mutant proteins at
the NusG-dependent terminator, trac (6), in the presence of different NusG derivatives. The strain RS1430 (see Table 1) was used in the assays. Rho and NusG
mutants together with the reporter construct are indicated. Error bars are obtained from the measurements of 5 independent colonies.
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Transcription was initiated from the PRM promoter. At first, a
stalled ECwas formed at the lac operator site in the presence of
the lac repressor, following which WT and Rho* mutants,
R221C and P235H, were added to induce the RNA release.
Time course of RNA release in the supernatant fractions were
estimated from the supernatant (S) and pellet (P) fractions (Fig.
3D), and the amount of fractions of RNA released were plotted
against time (Fig. 3, E–G). We observed that in the absence of
NusG, the time course of RNA release induced by theWT Rho
was slow and the rate of RNA release increased in the presence
of NusG (Fig. 3E). The RNA release rate was observed to be
increased by 2.5-fold by the Rho* mutants in the absence of
FIGURE 3. In vitro transcription assayswith the Rho*mutants.Autoradiograms showing the in vitro Rho-dependent transcription termination assays of the
WT and Rho*mutants using the templates having (A)H-19B TR1 and (B) trac terminators. Termination assays were performed both in the presence and absence
of NusG. In A, termination zones are marked by double sided arrows. In B, an immobilized DNA template having the trac terminator was used to measure the
terminated RNA. The termination zones are indicated by dashed lines. The reactions were fractionated into S (half of the supernatant) and P (half supernatant
pellet) fractions to identify the terminated RNA that appeared as released product. In both the experiments, concentrations of RNAP, Rho, and NusG were 25,
50, and 200 nM, respectively. C, schematic showing the formation of a stalled elongation complex (RB) downstream of the rut sites of the trac terminator using
the lac repressor. The elongation complex is immobilized via a 5-biotin-avidin linkage of the template with magnetic beads. Different components of this
stalled complex are indicated. D, autoradiograms showing the time course of RNA release from the EC stalled downstream of the trac terminator sequence as
induced by WT and Rho* mutants. RNA release by the WT Rho has been shown both in the presence and absence of NusG. S denotes half of the supernatant
and Pdenotes rest of the sample. RB represents the RNA corresponding to theposition of the stalled ECon this template. The 0min timepoints are the samples
that do not contain Rho. E–G, plots showing the fractions of released RNA against time from the RB, in the presence ofWT and Rho*mutants, P235H and R221C
both in thepresence and absence ofNusG as indicated. Average rates of RNA release (k) are indicated inside eachof theplots. The experimental data points are
fitted as described under ”Materials and Methods.“ Error barswere obtained from three independent measurements.
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NusG, and 4.5-fold increase was observed when NusG was
added (compare Fig. 3, E with F and G). This indicates that
compared with WT Rho, these Rho* mutants are capable of
inducing significantly faster RNA release both in the presence
and absence of NusG. This faster RNA release could imply that
these mutants have altered interactions with RNA as well as a
faster rate of ATP hydrolysis, which in turn might have
increased their rates of helicase activities.
To probe this, next we followed Rho-RNA interactions. Rho
has two RNAbinding sites: the primary RNA binding site (PBS)
at the N-terminal and the secondary RNA binding site (SBS) at
the central channel (1, 2).Wemonitored the interactions at the
PBS by following the fluorescence quenching of the fluorscein-
poly(dC)34 DNA (a 34-mer oligonucleotide) upon interaction
with WT and Rho* mutants (Table 2). This single-stranded
DNA selectively binds to the PBS (11). We observed that the
dissociation constants of poly(dC)34 did not change drastically
due to the Rho* mutations. We also tested the binding of WT
and Rho* mutants with other DNA oligos of similar size either
having a random sequence (non-rut oligo) or the rut sequence
of the TR1 terminator (rut oligo) (see “Experimental Proce-
dures”) using gel-shift assays. We estimated that WT and Rho*
mutants have comparable affinity for the rut oligo and all of
them showed insignificant binding to the non-rut oligo (data
not shown). These results suggest that interaction patterns in
the PBS did not change significantly in these mutants.
Next we estimated the affinity constants of the SBS of the
WTand theRho*mutants for anRNAoligo, rC25, bymeasuring
theKm of this RNA oligo from the RNA-induced ATPase activ-
ity of the Rho proteins (Table 2). This method, instead of a
direct binding assay, was used because this RNA oligo induces
enzymatic activities to the Rho protein. It should be noted that
theKm is a composite parameter that includes both binding and
catalytic steps. The Km values obtained with the Rho* mutants
were about 7–17-fold lower than what was obtained with the
WT Rho (Table 2). This strongly indicates that the Rho*
mutants have significantly higher affinity constants for the
RNA at the SBS.
It is likely that the tighter RNA binding at the secondary
channel would induce faster RNA-dependent ATP hydrolysis.
Wemeasured the amounts of ATP hydrolyzed at different time
points (0 to 20 min) in the presence of a fixed concentration of
the inducer, TR1 RNA (the rates of ATP hydrolysis were cal-
culated from the dynamic ranges of the plots; Table 2). We
observed that the Rho* mutants have 2.5–7.5-fold higher
rates of ATP hydrolysis compared with that of the WT Rho,
which is consistent with their tighter RNA-binding properties
at the SBS. The tighter RNA binding at the SBS and the faster
ATP hydrolysis properties of the Rho* mutants are suggestive
of the presence of distinctive conformational changes in their
central channel. Interestingly, the positions of the Rho* muta-
tions on the Rho structure are not at the central channel, rather
they are located far away from the SBS (Fig. 4, A and B). This
indicates that the mutations caused conformational changes
allosterically. In subsequent sections, we probed the nature of
these conformational changes at the SBS of the Rho* mutants.
Conformational Changes in the Central Channel of the Rho
Mutants—We employed partial proteolytic digestion using
trypsin and V8 proteases to map the changes in the surface
accessibility of specific regions of the Rho* mutants. We used
end-labeled Rho proteins to identify the proteolytically cleaved
sites. In Fig. 5A, partial cleavage ofWT and Rho* mutants were
induced with trypsin. P235H Rho showed hypersensitivity
around amino acids 181–184, compared with that observed
with the WT Rho. The hypersensitivity of the same region was
moderate in the case of R221C Rho. Due to the R221C change,
the cleavage was very weak at this position, and also the muta-
tion caused abnormalmobility of the cleaved fragments around
the 181–184 amino acid region. In Fig. 5B, the same experi-
ments were repeated with V8 protease. The major cleavage
products in all the cases were observed at the 211–215 glutamic
acid stretch. This region of R221C Rho showed the maximum
sensitivity toward V8. As R221C mutation is located near the
region of 211–215, this hypersensitivity could be a specific
effect of this mutation. So we probed the same V8 hypersensi-
tivity using the R221A Rho* mutant, which also has the similar
properties as R221C (see Figs. 1 and 2). We observed the same
pattern of V8 hypersensitivity for R221A Rho (Fig. 5C). Hence,
this hypersensitivity of the glutamic acid stretch defines a spe-
cific conformational changes of the Rho* mutants.Wemapped
these twohypersensitive regions (181–184 and 211–215) on the
outer wall of the central channel along the dimeric interfaces
(Fig. 5D), which suggests significant changes in local conforma-
tions in the channel of theRho*mutants. It should be noted that
amino acids 181–184 are part of the ATP binding pocket of the
central channel (18), and hence, conformation of this pocket
has also been altered especially in the P235H mutant.
From the enhanced RNA-binding affinity at the SBS (Table
2) and the faster ATPase activity (Table 2) results, we reasoned
that the P-, Q-, and R-loops structural elements in the central
channel (Fig. 6A) have undergone significant conformational
changes in the Rho* mutants, because the P-loop constitutes a
part of theATP-binding pocket and theQ- andR-loops directly
interact with the RNA in the SBS (2) (Fig. 6A). The flexibility of
these loops (17, 18) makes them susceptible to conformational
changes. We probed these putative conformational changes
using fluorescence spectroscopy by following the accessibility
of the site-specifically labeled fluorescent probes at these three
important structural elements, P-, Q-, and R-loops.
At first, we have used a fluorescent probe, Tb(III)-GTP,
which binds to the ATP binding pockets (19), to monitor the
changes in the spatial orientations of the P-loop. The free
Tb(III) becomes fluorescent upon complexationwithGTP (Fig.
6B). Fluorescence intensity of this complex further increased
upon binding to the ATP binding pockets of WT and Rho*
mutants (Fig. 6B) characterized by the two peaks at 488 and 547
nm. We assessed the accessibility of this pocket by measuring
the extent of fluorescence quenching with a neutral quencher,
acrylamide (20). The quenching constant, KSV, is directly pro-
portional to the accessibility of the fluorescent probe to the
quencher. We observed gradual quenching of the fluorescence
intensity with increasing concentrations of acrylamide in all the
cases characterized by upward curvatures in the Stern-Volmer
plots (Fig. 6C). However, the extent of quenching varied for
NusG-mediated Regulation of Transciption Termination
OCOTBER 21, 2016•VOLUME 291•NUMBER 43 JOURNAL OF BIOLOGICAL CHEMISTRY 22391
 by guest on M
ay 28, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
each of the proteins (Fig. 6C). The quenching constant (KSV)
was observed to increase to 2–3.5-fold for the Rho* mutants,
P235H and R221C, indicating the presence of more accessible
P-loop aswell as theATPbinding pockets in themutants allow-
ing better access of ATP molecules to this region. This obser-
vation is consistent with the hypersensitivity of this region to
the trypsin cleavage (Fig. 5A). This altered conformationmight
have also affected the rates of the ATPase activities (kcat of
ADP/Pi release) of these mutants indirectly (see Table 2).
Next to probe the state(s) of the Q- and R-loops, we intro-
duced single cysteine residues in these two loops that were sub-
sequently labeled with fluorescein malemide. Rho has a single
cysteine at 202 position. We at first made a “zero cysteine” Rho
(C202S change in theWTRho) and introduced single cysteines
via the following changes, T276C (Q-loop), S281C (Q-loop),
T286C (Q-loop), S323C (R-loop), and S325C (R-loop) (Fig. 7A,
see also the monomeric structures in Fig. 8). These single cys-
teine derivatives were constructed both on the WT and the
Rho* mutant, P235H. It should be noted that as Rho is a hex-
amer, one cysteine residue per monomer will be fluorescent
labeled. The hexameric structure of Rho revealed (Fig. 7A) that
except for the R-loop cysteine derivatives all the others are sur-
face exposed. The R-loop derivatives are partially buried. We
tested the ATPase as well as the RNA release activities from the
ECs (Fig. 7, B andC) of these single cysteine derivatives. Except
the T286Cmutation, all the others were either fully or partially
active in both assays. The activities of S323C and S325C mark-
edly improved when they were made on the Rho* mutant,
P235H. This reduction in activity is expected as the changes
weremade in the very important functional elements of Rho. In
general, P235HRho ismore efficient in the in vitro experiments
compared with theWT one (see also Fig. 3 and Table 2), so the
cysteine derivatives made on this Rho mutant were also more
efficient upon site-specific labelingwith fluorescein, each of the
cysteines would function as conformational reporters of the Q-
and R-loops. About 80% of the protein molecules were labeled
under our experimental conditions.
We used a fluorescence quenching technique with the neu-
tral quencher, acrylamide, to probe the microenvironment of
the Q- and R-loops. Upon excitation at 470 nm, fluorescein
emission was monitored in the 500 to 600-nm range (spectra
are not shown). Increasing concentrations of the acrylamide
induced gradual quenching, and the fractions of quenching
(F0/F) were plotted against the concentrations of the quencher
(Fig. 8, A–E). The nature of the curves as well as the quenching
constants varied from the positions of the cysteine residues,
indicating the effectiveness of the probes and the quenching
technique to monitor the changes in the microenvironments.
FIGURE 4. Locations of the Rho* mutants on the structure of hexameric Rho. A, schematic showing the locations of Rho* mutants on the Rho hexamer
structure (PDB 3ICE) in a closed conformation (18). B, distances of the positions of the Rho* mutants from the center of the RNA bound to the SBS.
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From these Stern-Volmer plots (Fig. 8, A–E), we made the fol-
lowing observations.
C202—These cysteines are the natural ones of Rho and are
located at the interface of the protomers. The downward bend
in the WT Rho curve indicates the presence of more than one
population of cysteines with variable accessibility. This might
have arisen from the asymmetrical open conformation of the
Rho hexamer (17). However, instead of a bended curve, an
upward curvaturewas observed for the P235HRho. Thismeans
cysteines of this Rho are present in more homogeneous envi-
ronment, but are less accessible (has 3-fold less KSV value)
than their WT counterparts.
Q-loop Cysteines (Cys-276, Cys-281, Cys-286)—Cys-276 and
Cys-281 are more accessible in P235H Rho characterized by
their higher KSV values. Cys-281 residues in P235H exhibited
heterogeneity, indicating that Q-loops in some of its subunits
are relatively buried. This trend was not observed for the
Q-loops of theWTRho. Accessibility of Cys-286 inWTand the
mutant was similar.
R-loop Cysteines Cys-325 and Cys-323—Cys-325 in WT and
P235H Rho were quenched in a comparable fashion. Interest-
ingly, unlike WT Rho, Cys-323 of P235H Rho could not be
labeled by 5-fluorescein malemide (data not shown), which
could be due to its complete burial inside the structure. To
further support this conclusion, we assessed the ability of this
cysteine residue to form disulfide bridges with the nearby cys-
teines. We used a reducing agent copper phenanthroline
(Cu-P) (9) to induce the Cys-Cys bond (Fig. 8F). We observed
that partially exposed Cys-323 (see Fig. 7A also) of theWTRho
could form disulfide linkage with neighboring cysteine from
anothermolecule of Rho as intra-molecular bonding is not pos-
sible due to the distance constraints (18). Interestingly, these
bonds were not at all formed by Cys-323 of P235H Rho that
further confirmed that in this Rho*mutant this R-loop cysteine
is totally buried in the structure (Fig. 8F). This same assay with
other cysteines of both the Rho proteins revealed that all of
them are surface accessible to form the disulfide bridges (data
not shown). It should be noted that the cross-linked product
migrates closer to the position of a tetramer. However, theoret-
ically an inter-molecular dimer is likely to be the only product.
The abnormal migration in SDS-PAGE could have arisen from
an unusual conformation of the cross-linked product.
FIGURE 5. Probing the conformational changes in the Rho* mutants. Autoradiograms showing the cleavage patterns of the radiolabeled WT and Rho*
mutants in the presence of (A) trypsin and (B) V8 proteases under the indicated conditions. Profiles of the cleavage intensities are aligned with the patterns
shown in the autoradiograms. In A for the ease of comparison, cleavage profiles ofWT (—) and Rho*mutants (- - -) and in B forWT (—), R221C (- - -), and P235H
(- - -) profiles are overlapped. The cleavage positions were identified from the proteolytic digestions with CNBr (at Met), Lys-C (at Lys), and Arg-C (at Arg) as
indicated on the side of the autoradiograms. C, autoradiograms showing the V8 cleavage patterns ofWT and R221A Rhomutant under the same conditions as
above. The V8 cleavage sites were identified in similar ways as described above. Profile plots of the cleavage intensities are shown adjacent to the autoradio-
gram.D, the trypsin and V8 hypersensitive regions on the amino acid sequence of Rho are shown. These regions are also indicated on the structure of the Rho
dimer (V8, blue; trypsin, red). Locations of the Rho* mutations are also indicated.
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Taken together all the fluorescence experiments (Tb-GTP
and fluorescein), we concluded that significant conformational
re-orientations of the P-, Q-, and R-loops have occurred in the
Rho*mutants, P235H, characterized bymore surface accessible
P- and Q-loops together with a buried R-loop.We predict sim-
ilar type of changes in the other Rho* mutants as well. These
changesmay lead to the formation ofmore “open” central chan-
nel, which enables the mRNA to chaperone into the channel
more easily. These structural alterations in the channel might
be the main reason for the faster ATPase activity (Table 2) and
the tighter binding to RNA at the SBS (Table 2) of the Rho*
mutants.
However, it can be argued that the structural changes in dif-
ferent single cysteine derivatives arose due to the fluorescence
labeling itself, and it is difficult to rule out that possibility. How-
ever, we like to incline to aforementioned interpretations,
because we are emphasizing the relative changes between the
WT and mutant Rho proteins.
Functional NusG Binding Site(s) on Rho and the Allosteric
Effect—The aforementioned detailed characterizations of the
Rho* mutants strongly suggested that NusG stimulates the
Rho-termination process by exerting its effects at the central
channel of the latter. The next task was to identify the func-
tional interaction site(s) of NusG on the Rho to understand
whether the site (s) of action coincides with the site(s) of bind-
ing. In our earlier study (9) (Fig. 9B), we reported that Rho
mutantsV203L,M205A,V227N, andV228Nhad caused partial
defects in Rho-NusG CTD binary complex formations in vitro.
In the same study, Lys-224 of Rho was also shown to be proxi-
mal to the NusG-CTD in this binary complex. All these in vitro
FIGURE 6. P-, Q-, and R-loops of Rho hexamer and TbCl3 fluorescence. A, crystal structure of Rho hexamer (PDB ID 3ICE) highlighting the functionally
important loops and the RNA at the central channel by the indicated colors. B, fluorescence emission spectra of TbCl3 under different conditions as indicated.
Two distinct peaks of the TbCl3 at 488 and 547 nm are visible. C, modified Stern-Volmer plots to determine the quenching constant (KSV) and the nature of
quenchingbyaneutral quencher, acrylamide. F0 and Fare the fluorescence intensities of Tb(III)-GTPbound to theATP-binding siteof theWTandRho*mutants,
in theabsenceandpresenceofdifferent concentrationsof acrylamide, respectively. AverageKSV values are calculated fromthe initial slopesof the curves.Errors
were calculated from two to three measurements.
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assays were performed outside the EC. So to confirm whether
the region encompassed by these mutations constitutes the
functional Rho-NusG interaction sites, we employed various in
vivo assays with these mutants (Fig. 9, C and D). In the present
analyses, we also added Q193A mutant due to its proximity to
this region of Rho.
Overexpression of NusG-CTD fragment causes toxicity to
the cells because it titrates away Rho from the solution and
thereby prevents it from interacting with the EC-bound NusG
(Fig. 9A). We hypothesized that if the above mentioned Rho
mutants haveweaker interactionwith theNusG-CTD, this tox-
icity would be alleviated. We transformed MG1655 (RS1305)
strains, expressing one of the Rho mutants from a low-copy
plasmid, pCL1920, with the arabinose-inducible plasmid
pHYD3011-NusG-CTD. Serial dilutions of the overnight cul-
tures were spotted on the LB plates. Overexpression of the
NusG-CTD fragmentwas achieved by adding 0.2% arabinose in
the plates. We observed that high level expressions of the CTD
fragment caused toxicity only to the strains expressingWTRho
(Fig. 9C, right panel). Strains expressing mutant Rho proteins
did not show significant growth defects. This suggests that
these Rho mutants have weaker interactions with NusG under
in vivo conditions also.
If these Rho mutants are defective in NusG binding, then
they might exhibit synthetic defect with NusG-CTD mutants,
G146D and L158Q, defective for Rho binding (9) (Fig. 1C). In
other words, the partial defects exhibited by these Rhomutants
with the WT NusG would be enhanced in the presence of
NusG-CTDmutants. Presence of both Rho and NusGmutants
might cause synthetic lethality as the Rho-NusG interaction in
vivo is essential.
To test the synthetic lethality, MC4100 strains having chro-
mosomal copies of the NusG mutants, G146D (RS1514) and
L158Q (RS1523), were used. Different Rho mutants were
expressed from a low-copy plasmid (Fig. 9D).We observed that
the Rhomutants, Q193A, V203L, andM205A, showed extreme
growth defects when they attempted to grow in the presence of
these NusG mutants, indicating the presence of strong syn-
thetic lethality for these combinations. Twoother Rhomutants,
K224C and V228N, did not show a appreciable growth defect
when expressed in the presence of the NusG mutants.
Based on these in vivo assays, we concluded that the Rho
mutants Q193A, V203L, and M205A are the most defective in
interacting with NusG, and thereby the region encompassed by
them defines the functional interaction site(s) for NusG on the
Rho hexamer. The region defined by these mutants partially
overlaps with the region that was defined from the in vitro pull-
down or cross-linking assays (9) (Fig. 10A). Most interestingly,
however, is that the NusG-binding site(s) on Rho is located far
away from the central channel (40Å) and also the locations of
FIGURE 7. Single Cys derivatives of Rho. A, location of the single cys substitutions on the hexameric structure of Rho (PDB ID 3ICE). The space-filled models
were prepared using PyMOL. Positions of the mutations are indicated. The color codes are as follows: T276C, red; S281C, green; T286C, cyan; T323C,magenta;
S325C, blue. In first crystal structure the view is from the side of the PBS, in the second is from the side of the SBS, and the third is a side view. The RNA in the
central hole of the hexamer is indicated in schematic form as red spirals. B, autoradiograms showing the in vitro Rho-dependent transcription termination
assays of the WT and Rho* mutants with single cysteines at different places of the loop structures on the tR1 terminator. The run-off (RO) products and the
termination zones of each of the Rho derivatives are indicated. Concentrations of RNAP, DNA, and Rho were 25, 10, and 50 nM, respectively. Template for the
in vitro transcription assay was made by PCR amplification on the pRS22 (T7A1-H-19B TR1) using oligo pairs RS83/RK23B. C, bar diagram showing the rates of
ATPase activities of all the single cysteine Rho derivatives induced by the tR1 RNA. Concentrations of Rho and RNA were 25 nM and 20 M, respectively.
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Rho* mutants do not overlap with these sites (Fig. 10A). We
concluded that the NusG exerts its effect at the Rho central
channel allosterically by binding at away site(s).
Discussion
In this present study, we have attempted to understand the
mechanism of NusG-mediated stimulation of the Rho-depen-
dent transcription termination in E. coli. We isolated Rho
mutants (Rho*) that are capable ofmaking the cells viable in the
FIGURE 8. Probing the conformational changes at the central channel of
the Rhomutants. Locations of different single cysteine derivatives (left pan-
els) and correspondingmodified Stern-Volmer plots obtained from the acryl-
amide quenching of the fluorescein molecule attached to each of the cys-
teine derivatives are shown in A–E. Due to non-linear nature of the plots, we
used the modified Stern-Volmer equations to fit the curves as described
under ”Materials and Methods.“ We calculated the KSV from the initial slopes
of the curves,which approximately equals to the respectivedynamicquench-
ing constants. The P-, Q-, R-loops are indicated in the structurewith the single
cysteines as spheres. F, 12% (w/v) SDS-PAGE showing the formation of inter-
molecular disulfide bonds between the cysteines of neighboring molecules
using copper phenanthroline (Cu-P) as a reducing agent.
FIGURE 9. Functional interaction sites ofNusGon theRhohexamer.A, the
scheme describing the CTD toxicity assay. The CTD of NusG has more affinity
for the Rho than the full-length NusG, and therefore, its overexpression
titrates out the latter from the elongation complex leading to conditional
toxicity of the cells. Schematics show the representation of the toxicity of the
overexpressedNusG-CTD in thepresenceofWTRho.B, aminoacid sequences
of the region of Rho that cross-links to the NusG-CTD (9). The positions of the
point mutations in this region are defective in Rho binding in vitro. C,
MG1655rho strains (RS1305) expressingWT and the indicated Rhomutants
from the pCL1920 plasmids were transformed with arabinose-inducible
pHYD3011 (a modified pBAD plasmid) plasmid expressing the NusG-CTD
fragment. Different dilutions of theovernight culture of the strainswere spot-
ted on LB plates either in the absence (0%) or presence of 0.2% arabinose to
check the growth defects by the overexpression of the NusG-CTD fragment.
Dilutions are indicated on the left side of the figures, which indicate the plat-
ting efficiencies.D,growth characteristics ofMC4100racrho strains having
either WT or G146D or L158Q nusGmutants in the chromosome in the pres-
ence of different Rho derivatives, WT, V203L, M205A, K224C, and V228N
expressed from low-copy pCL1920 plasmids. After transformingwith the Rho
plasmids, the chromosomal rho was removed by P1 transduction and the
transductants were re-streaked on the LB plates to check the synthetic
lethality.
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absence of NusG as well as suppressed the defects of NusG-
CTD mutants defective for Rho binding (Figs. 1–3). These
results led us to reason that the Rho* mutants had acquired
properties that NusG may impart to Rho. Analyses of the in
vitro properties of these Rho* mutants revealed that they have
acquired distinct conformations in the central channel charac-
terized by the spatial re-orientations of the structural elements
P-, Q-, and R-loops (Figs. 5, 6, and 8), which enabled them to
have tighter RNA binding at the SBS as well as faster ATPase
activities (Table 2). We propose that EC-bound NusG induces
similar properties to the SBS as well as the central channel of
the hexameric Rho. Finally, from the delineations of the func-
tional interaction sites of NusG, we concluded that it exerts its
effect at the SBS of Rho allosterically from a distance (Figs. 9
and 10A).
Two kinds of crystal structures of the Rho hexamer have
been reported: the open (17) and the closed ring structures (18).
In the asymmetrical open ring structure, the PBS is occupied by
oligonucleotides, whereas in the more symmetrical closed ring
structure both the PBS and the SBS are occupiedwithDNAand
RNA oligonucleotides, respectively. Based on these sequential
occupations of the PBS and SBS, we have described open (OC)
to close complex (CC) conversion leading to Rho activation via
multiple equilibria involving isomerization step(s) as described
in Fig. 10 (6, 21). These isomerization step(s) involve major
conformational changes in the central channel including RNA
and ATP binding at the P-, Q-, and R-loops. In the present
report, we provided strong evidence that NusG exerts its stim-
ulatory effect on Rho by altering the interactions at the SBS
through reorientations of those loops. We propose that NusG
targets the open (OC) to close (CC) isomerization step(s) allos-
terically, accelerating the forward reactions (k2) to form the
irreversible translocation competent state of Rho. This acceler-
ation is more important when Rho-RNA binding at the PBS is
relatively unstable. By increasing the k2, the equilibria shifts
toward the CC form, which in turn stabilizes the interaction.
FIGURE 10. A, locations of the (i) amino acids important for NusG-binding, (ii) Rho* mutants, and (iii) hypersensitive amino acids are indicated on a Rho-dimer
structure (PDB code 2HT1). The NusG-binding site is circled, where amino acids in yellow are K224C, V227N, V228N, and those in green are V203L, Q193A, and
M205A. B, schematic showing the kinetic/equilibrium steps during the conversion ofOC to CCof the Rhohexamer. Putative step(s) those are targeted byNusG
are indicated. ATP-binding and hydrolysis steps are also shown. Hexameric structures were based on the coordinates using PDB codes 3ICE and 1PVO,
respectively.
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The overall stimulation of the Rho-dependent termination pro-
cess by NusG is the direct outcome of the aforementioned
acceleration of the rate-limiting steps. This proposed NusG-
induced alterations of interactions in the SBS is likely to influ-
ence the translocation as well as the helicase properties of the
Rho, which might have also contributed in the faster rate of
RNA release and the early termination events of the Rho*
mutants (Fig. 3).
Rho has six NusG-binding sites, one on each subunit. How-
ever, the stoichiometry in the Rho-NusG complex was mea-
sured to be 1:1 Rho hexamer:NusGmonomer (12), which indi-
cates that at a given time point NusG occupies one of the six
sites on the Rho. From the aforementioned model, it is likely
that NusG binds to the OC state of the Rho (Fig. 10B), and due
to the intrinsic asymmetry of this state, it might prefer one
particular subunit of Rho for binding. It is not clear to us how
suchmajor conformational changes are induced byNusG at the
central channel of Rho by occupying only one of the six sites. If
Rho directly binds to the EC-bound NusG, there is a possibility
that sequential occupancy of subsequent sites on each of the
Rho subunits could occur during the elongation process due to
the changes in the orientations of the NusG-CTD along with
the moving EC.
The binding affinity for different rut sites having different
RNA-sequence compositions vary widely, and therefore many
of these sites are likely to be suboptimal rut sites characterized
by C-poor sequences. To catch-up a rapidly transcribing EC, it
is important that Rho undergoes fast OC to CC conversion at
the rut sites via the multiple isomerization steps (Fig. 10B),
which is likely to be slower at the suboptimal rut sites due to the
weaker binding at PBS (because of high k1). We propose that
on those rut sites, NusG-mediated acceleration at the recruit-
ment steps is essential, and thereby makes NusG an important
component of Rho-dependent termination, especially under
the in vivo conditions. Consistent with this proposal, genomic
studies (4)4 revealed that about one-third of theRho-dependent
termination events are NusG-dependent. Earlier we have
shown that a bona fide NusG-dependent terminator, trac of the
rac prophage (6), has a weaker rut site characterized by slow
formation of the translocation-competent Rho (CC). Hence,
the silencing of this prophage through the Rho-dependent ter-
mination at trac is actually regulated by the Rho-NusG interac-
tion (3).
Does Rho-NusG CTD Interaction Modulate NusG NTD-
RNAP Interactions?—Interaction of NusG-NTD with the two
structural elements, -clamp helix (CH) and -gate loop (GL)
near the non-template DNA strands (7) of the EC causes anti-
pausing and increase in the rate of transcription elongation. It is
possible that upon interaction with the NusG-CTD, Rho could
alter the NusG NTD-RNAP interaction via the NusG-linker
region (Fig. 1C), which might induce pausing instead of anti-
pausing to the EC. RfaH, a NusG family protein, has similar
NTD conformations as NusG and interacts at the similar site(s)
of the EC, but induces pausing at specific sites called the ops
sites (7). It is alluring to suggest that Rho-NusG CTD interac-
tions allosterically exert shuttle conformational changes to the
NusG-NTD so that the latter behaves functionally similar to
RfaH-NTD, and induces enhanced pauses at the Rho-termina-
tion sites. This enhanced pausing could act as another way of
stimulating Rho-dependent termination by NusG. NusG-in-
duced pause has been documented for Bacillus subtilis NusG
(22).
Experimental Procedures
Materials
NTPs were purchased from GE Healthcare. [-32P]ATP
(3000 Ci/mmol) and [-32P]CTP (3000 Ci/mmol) were
obtained from Jonaki, BRIT (Hyderabad, India). Antibiotics,
IPTG, lysozyme, DTT and bovine serum albumin (BSA) were
obtained from U.S. Biochemical Corp. Restriction endonu-
cleases, polynucleotide kinase, and T4 DNA ligase were from
New England Biolab. E. coli RNA polymerase holoenzyme
was purchased from Epicenter Biotechnologies. Streptavidin-
coatedmagnetic beadswere fromPromega.TaqDNApolymer-
ase was obtained from Roche Applied Science. Site-directed
mutagenesis kit was purchased from Stratagene. Ni-NTA-aga-
rose beadswere fromQiagen and Sigma. Details of the bacterial
strains and plasmids are described in Table 1.
Screening and Isolation of RhoMutants That Function
Independently of NusG
RS862 (MG1655rac, rac::tet) was at first transformedwith a
plasmid overexpressing the NTD of NusG (NusG-NTD) from
the arabinose-controlled PBAD promoter. The resulting strain
was electroporated with a mutagenized plasmid library carry-
ing the rho (pHYD567). The transformants were at first
streaked on a LB plate to get a master plate. The colonies were
then further streaked on LB plates supplemented with 0.2%
arabinose. The presence of arabinose overexpressed the NusG-
NTD fragment (data not shown). Healthy colonies on the arab-
inose plates were selected. Rho mutant plasmids were isolated
from these colonies, and the mutations were confirmed by
sequencing. The mutagenized plasmid library were prepared
by growing the pHYD567 in the mutator strain, XL-Red
(Stratagene).
Growth Assays
The strain RS862 was at first transformed with the plasmid
pCL1920 carrying eitherWTormutant rho, andwere plated on
the LB plates. To check the growth abilities of these trans-
formed strains in the absence of nusG, the nusG::KanR cassette
was moved into them by P1 transduction. These plates were
incubated at 37 °C for20 h to record the growth of the colo-
nies (Fig. 1B).
To study the growth-defect suppression of the NusG
mutants (G146D and L158Q) by the aforementioned Rho*
mutants, strain RS1305 (MG1655rho, having the pHYD1201
shelter plasmid expressing rho) was at first transformed with
plasmids pCL1920 carrying eitherWT or mutant rho and were
plated on the LB plates in the absence of IPTG to remove the
rho shelter plasmid. Resultant strains were then transformed
with the pHYD3011 plasmids carrying either WT or the4 V. Valabhoju, S. Agrawal, and R. Sen, unpublished data.
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mutant nusG (G146D and L158Q). Finally, the chromosomal
nusG (nusG::kanR) was removed by P1 transduction and the
transductants were plated to assess the growth defect suppres-
sion by the Rho mutants (Fig. 1C). It should be mentioned that
the aforementioned procedure of creating the nusG deletion
retained the NusG-NTD fragment in the chromosome. How-
ever, this fragment does not supportNusG function in vivo, and
thereby does not interfere in our studies. Whenever required,
rho was deleted by P1 transduction using the lysate grown on
RS330 that does not have gene duplication (23) as was observed
in the original keio collection.
For the NusG-CTD overexpression-mediated toxicity
assays, strain RS1305 was at first transformed with plasmids
pCL1920 carrying either WT or different mutant rho and were
plated on the LB plate in the absence of IPTG to remove the
shelter plasmid expressing a WT copy of rho. Once the shelter
plasmid was removed, these strains were transformed with the
plasmid (pHYD3011, a pBAD derivative) carrying the CTD
domain of NusG. Arabinose-induced high-level of expressions
(data not shown) of this domain from these plasmids are toxic
to the cells. Serial dilutions of the overnight culture of each of
these transformants were spotted both in the absence and pres-
ence of 0.2% arabinose and were grown overnight at 37 °C (Fig.
9C). For the synthetic lethality assays with the Rho mutants
(V203L, Q193A, M205A, K224C, and V228N) in combination
with NusG mutants (G146D, L158Q), RS1514 (MC4100
nusGG146D), and RS1523 (MC4100 nusGL158Q) were first
transformed with plasmids pCL1920 carrying either WT or
mutant rho. Finally, the chromosomal rho (rho::kanR) was
removed by P1 transduction and the transductants were plated
TABLE 1
Strains and plasmids used in the study
HMK, heart muscle kinase.
Genotype Ref.
Strains
RS 257 MC4100 galEP3 rac (GJ3161)
RS330 GJ3161rho:: KanR , with pHYD1201 shelter plasmid, AmpR 23
RS 734 RS257 with RS45 lysogen carrying Plac-nutR-LacZ
RS862 MG1655 WT rac strain 6
RS1017 RS257 with RS45 lysogen carrying Plac-H19BnutR-trpt-LacZ
RS1263 MG1655 K12 WT strain
RS1305 MG1655rac carrying marker less rho (rho::FRT) with pHYD1201 AmpR (AI) This study
RS1428 RS257 with RS45 lysogen carrying PRM-racR-trac-lacZYA 6
RS1430 RS257 with RS45 lysogen carrying PRM-racR-trac-lacZYA with marker less rho::FRT with pHYD1201, AmpR 6
RS1458 RS1017, flipped out Kan cassette from RS 1017 (Plac-H19B nutR-trpt-lacZ) 6
RS1490 Rs734 with flipped out Kan cassette made rho with keio collection rho lysate AI (rho::FRT) 6
RS1514 MC4100 carrying PRM-racR-trac-lacZYA with G146D nusG in chromosome 6
RS1523 MC4100 carrying PRM-racR-trac-lacZYA with L158Q nusG in chromosome 6
Plasmids
pHYD1201 3.3-kb HindIII-SalI fragment carrying rho subcloned from pHYD567 into HindIII SalI sites of pAM34
(pMB1; IPTG dependent replicon, AmpR)
23
pRS22 pTL61 T with pT7A1-H-19B nutR-TR_T1T2-lacZYA, AmpR 20
pRS96 pET21b with WT rho cloned at NdeI/XhoI site, His-tag at C-terminal; AmpR
pRS604 T7A1-TR1 fragment cloned at Hind III site of pRS22. 24
pRS613 pET21b with R221C rho cloned at NdeI/XhoI site, His-tag at C-terminal; AmpR This Study
pRS630 pET21b with P235H rho cloned at NdeI/XhoI site, His-tag at C-terminal; AmpR This study
pRS649 WT rho with its own promoter cloned at HindIII/SacI sites of pCL1920; SpR, SmR 11
pRS695 pHYD3011 WT nusG, AmpR 9
pRS698 pHYD3011 N-terminal domain nusG, AmpR 9
pRS699 pHYD3011 C-terminal domain nusG, AmpR 9
pRS700 pHYD3011 G146D nusG, AmpR 9
pRS728 pHYD3011 L158Q nusG, AmpR 9
pRS729 pHYD3011 V160N nusG, AmpR 9
pRS766 pcp20 (ts), Flp recombinase, AmpR, CamR 25
pRS900 pET 21b with R221A rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pRS961 pET 21b with WT with C202S rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pRS967 P235H rho with its own promoter cloned at HindIII/SacI sites of pCL1920; SpR, SmR This study
pRS1352 (PRM-racR-timm-lacZYA) cloned at EcoRI-SmaI of pK8628, AmpR 6
pRS1439 V203L rho with its own promoter cloned at HindIII/SacI sites of pCL1920; SpR, SmR This study
pRS1440 Q193A rho with its own promoter cloned at HindIII/SacI sites of pCL1920; SpR, SmR This study
pRS1444 M205A rho with its own promoter cloned at HindIII/SacI sites of pCL1920; SpR, SmR This study
pRS1493 R221C rho with its own promoter cloned at HindIII/SacI sites of pCL1920; SpR, SmR This study
pRS1768 R221A rho with its own promoter cloned at HindIII/SacI sites of pCL1920; SpR, SmR This study
pRS1492 I168V rho with its own promoter cloned at HindIII/SacI sites of pCL1920; SpR, SmR This study
pRS1532 pET 21b with I168V rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pRS1677 pET 21b with R221C rho cloned at NdeI/XhoI site, HMKHis tag at C-terminal; AmpR This study
pRS1678 pET 21b with R221A rho cloned at NdeI/XhoI site, HMKHis tag at C-terminal; AmpR This study
pRS1676 pET 21b with P235H rho cloned at NdeI/XhoI site, HMKHis tag at C-terminal; AmpR This study
pRS1703 pET 21b with T276C C202S rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pRS1704 pET 21b with S281C C202S rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pRS1705 pET 21b with T286C C202S rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This Study
pRS1706 pET 21b with S325C C202S rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pRS1707 pET 21b with P235H C202S rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pRS1709 pET 21b with P235H T276C C202S rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pRS1710 pET 21b with P235H S281C C202S rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pRS1711 pET 21b with P235H T286C C202S rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pRS1712 pET 21b with P235H T323C C202S rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pRS1713 pET 21b with P235H S325C C202S rho cloned at NdeI/XhoI site, His tag at C-terminal; AmpR This study
pK8628 pTL61T with Plac-H19BnutR TR1-lacZAY, AmpR 26
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to assess the synthetic lethality of the NusG mutants together
with the Rho mutants (Fig. 9D).
In Vivo Rho-dependent Transcription Termination Assays
For the in vivo termination assays, we have used reporter
system, PRM-trac-lacZYA (NusG-dependent terminator trac
fused to lacZ (6). Transcription was initiated from either PRM
promoters. These experiments were performed in theMC4100
strain RS1430 containing the trac-lacZ reporter cassette. In all
these strains chromosomal rho was deleted and this function
was supplied from a shelter plasmid. To introduce the Rho*
mutants, strain RS1430 was first transformed with pCL1920
plasmids carrying eitherWT or mutant rho and were plated on
the LB plate in the absence of IPTG to remove the Rho shelter
plasmid. Resultant strains were then transformed with
pHYD3011 plasmids carryingWT andmutant nusG, following
which chromosomal nusGwas deleted by P1 transduction (Fig.
2B). In vivo termination efficiencies at different Rho-dependent
terminators were estimated by measuring the -galactosidase
activities the following the standard protocols using microtiter
plates and the Spectramax Plus plate reader (11).
Preparations of Rho*Mutants
Rho* mutants obtained from genetic screening were cloned
in pET21b vectors, and purified using Ni-NTA beads (Qiagen)
as per the manufacturer’s protocol. The proteins eluted from
the Ni-NTA columns were further purified by passing through
a heparin-Sepharose column (Amersham Biosciences). To
avoid the contamination of the WT Rho expressed from chro-
mosome, the purification was performed in the presence of 1 M
NaCl. As the dissociation of the subunits occurred at high salt,
non-His-taggedWTprotomers, if present, were removed in the
wash fractions. CD spectra of different mutants were similar to
that of theWTRho (data not shown), indicating that the overall
structural integrity of the mutants was intact. P103L, P235H,
and R221A were constructed by site-directed mutagenesis.
Preparations of Single Cys Derivatives of Rho
All the single Cys derivatives of Rho were constructed by
site-directed mutagenesis using the Stratagene kit. First, the
onlyCys residue of theWTRho (at 202; pRS96)was removed by
introducing C202S mutations that yielded a zero Cys Rho
(pRS961). The single Cys derivatives, T276C (Cys-276), S281C
(Cys-281), T286C (Cys-286), T323C (Cys-323), and S325C
(Cys-325) were made using pRS961 as a template for WT Rho.
Similarly single Cys derivatives for Rho P235H were made on
the zero Cys P235H-C202S (pRS1707) as a template. All these
derivatives were His-tagged and the same purification proce-
dures were followed, except that 20 mM -mercaptoethanol
was used in the buffers using Ni-NTA columns and was
replaced with 50 mM DTT in the subsequent steps to avoid
disulfide formations. The serines (Ser) and threonines (Thr)
where selected based on their locations in the central channel of
Rho and their proximity to the secondary RNA binding site.
Templates for in Vitro Transcriptions
Linear DNA templates for in vitro transcription assays were
made by PCR amplification from the plasmids, pRS22 (PT7A1-
H19-BtR1) and pRS1352 (PRM-racR/trac) using the oligo pairs
RS83/RS845 andRS83/RS956. To form a road block (RB) on the
template, a 22-bp lac operator sequence was inserted after the
trac terminator using a downstream primer having the lac oper-
ator sequence. A transcription elongation road block is formed
at this sequence in the presence of lac repressor. To immobilize
the DNA templates to the streptavidin-coated magnetic beads
(Promega), a biotin group at the 5-end of the templates was
incorporated by using a biotinylated primer RS83. In the afore-
mentioned templates, transcription was initiated from a PRM
promoter.
In Vitro Transcription Assays
We performed single and multiple rounds of in vitro tran-
scription assays for the PT7A1 and PRM promoters, respectively.
Since the latter promoter is weak, to improve the yield of RNA,
we omitted rifampicin from the reactionmixtures. Single round
transcriptions were performed on PT7A1-H19-BtR1 template in
the presence of rifampicin in the transcription buffer (T-buffer;
25 mM Tris-HCl, pH 8.0, 5 mM MgCl2, 50 mM KCl, 1 mM DTT,
and 0.1 mg/ml of BSA). At first, a 23-mer elongation complex,
EC23, was formed by mixing 5 nM DNA template, 25 nM RNA
polymerase, 175mM adenylyl (3-5)-uridine, 5M each of ATP
and GTP and 2.5 M CTP. [-32P]CTP (3000Ci/mmol, BRIT,
Hyderabad) was used for labeling the transcripts. This EC was
then chased with 250 M NTPs for 15 min. For the PRM-racR/
trac template, it was immobilized to the streptavidin-coated
beads to assess the terminated products. Reactionswere carried
out in the transcription buffer (T-buffer) at 37 °C for 10 min.
Concentrations of all the NTPs were 250 M, except that CTP
was 50 M. [-32P]CTP (3000 Ci/mmol, BRIT, Hyderabad) was
used for labeling the transcripts. Concentrations of DNA,
RNAP, Rho, and NusG were 5, 25, 50, and 200 nM, respectively.
At the end of the reactions, tubes were held against a magnetic
stand and half of the supernatant (S) was removed and directly
mixed with formamide loading dye. The rest of the mixture (P;
half of the supernatant and pellet) was phenol extracted and
mixed with the loading dye. Samples were run onto 6%
sequencing gel and analyzed by FLA-9000 PhosphorImager
(Fuji) (Fig. 3A).
For the RNA release assays from the stalled ECs, the PRM-
trac-lacO template immobilized on streptavidin-coated mag-
netic beads was used. 100 nM lac repressor was added to the
DNA templates to form a road-blocked EC.On this template, at
first a 23-mer EC (EC23) was formed by initiating the reactions
with 175Madenylyl (3-5)-uridine, 5mMGTP, 5mMATP, 2.5
mM CTP, and [-32P]CTP (3000 Ci/mmol). The EC23 was then
chased with 250 M each of the NTPs for 2 min to form the
stalled EC, following which excess NTPs were removed by
washing the beads thoroughly. 50 nM Rho and 200 nM NusG
(when required) were added to the stalled EC and 10l of sam-
pleswere removed at the indicated time points, separated into S
(half of the supernatant) and P (other half of supernatant 
pellet) on the magnetic stand. The rest of the procedures were
same as described above (Fig. 3D). The fractions of released
RNA ((2S)/(S)  (SP)) were plotted against time and the
points were fitted to a curve following exponential rise equa-
tions either of the forms: y  a (1-expbx) or y  y0 
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a(1-expbx), where “b” denotes the rate, “a” is amplitude of the
RNA release process, and “y0” is minimum value of y at 0 time
point. If a lag is observed in the RNA release kinetics, it was
fitted to a sigmoidal equation of the form: y  y0  (a)/[1 
(x/x0)b], where “x0” is the inflection point of the curve and b is
the slope (Fig. 3, E–G).
Binding Assays of Rhowith Poly(dC)34 and Other
Oligonucleotides
The primary RNA-binding property of the WT and mutant
Rho proteins was measured by using a 5-fluorescein labeled
34-merDNAoligo (dC34) (27). Oligo(dC)34 specifically binds at
the primary PBS (11) of Rho. The fluorescence experiments
were performed in the buffer containing 25 mM Tris-HCl (pH
8.0), 5mMMgCl2, 50mMKCl, 1mMDTT, and 0.1mg/ml of BSA
at 25 °C in a Hitachi F7000 fluorescence spectrophotometer,
under CATmode, with a PMT voltage of 700 V and scan speed
of 240 nm. Excitation was at 470 nm, whereas the emission
range was from 500 to 600 nm. Quenching of fluorescence
intensity of 10 nM fluorescein-(dC)34 upon addition of increas-
ing concentrations of Rho was used as a measure for determin-
ing the primary RNA binding. The ratio of the initial fluores-
cence intensity at 520 nm (F0) and that obtained upon addition
of each concentrations of Rho were plotted against concentra-
tions of Rho. The plots were fitted to a hyperbolic equation of
the form, y (a b)/(b x), to obtain the binding isotherms.
The b values gave the measure of dissociation constant (Kd)
(Table 2).
Binding of other DNA sequences to the PBS of the WT and
different Rho mutants were measured qualitatively by gel-shift
assays using radiolabeled DNA oligos (data not shown). We
have used the following oligonucleotides for these assays: (i)
oligo with the tR1 rut site sequence (RS1387) CCCCGCTCT-
TACACATTCCAGCCCTGAAAAAGGG and (ii) an oligo
with a “non-rut” sequence (RS1386) TGCAGGCCGAAA-
GATTTTTTTAACTATAAA. The gel-shift assays were per-
formed using 10 nM of radiolabeled oligo in the T buffer with
different concentrations ofWTormutant Rho (10–50nM) pro-
teins. The reactionmixtures were supplementedwith 10% glyc-
erol and incubated at 37 °C for 10 min before loading onto a
5–15% gradient native acrylamide gel. Gels were run in 0.5
TBE buffer in a cold room and the signals were analyzed by
PhosphorImager.
Measurements of the Rate of ATP Hydrolysis
The rates of RNA-dependent ATP hydrolysis of WT and
mutant Rho proteins were measured using tR1 RNA, contain-
ing the rut sites of the tR1 terminator. DNA templates for tran-
scribing this RNA were prepared by PCR amplification from
plasmid pRS604 using the RS139/RS341 oligo pair. The tR1
RNAwasmade from this template using theMega transcript kit
(Ambion). ATP hydrolysis was assayed by monitoring the
release of Pi from ATP that was observed on the polyethyleni-
mine TLC plates using 0.75 M KH2PO4 (pH 3.5) as a mobile
phase buffer. The hydrolysis reactions were performed in T
buffer (25mMTris-HCl, pH 8.0, 50mMKCl, 5mMMgCl2, 1mM
DTT, and 0.1 mg/ml of BSA) at 37 °C. The rate of ATP hydro-
lysis of 100mMATP together with [-32P]ATP (3500 Ci/mmol;
BRIT, India) weremeasured using 50 nMRho. The reaction was
initiated by the addition of 0.2 M RNA. Aliquots were
removed, and the reactionswere stoppedwith 1.5 M formic acid
at various time points. Release of Pi was analyzed by exposing
the TLC sheets to a PhosphorImager screen and subsequently
by scanning using Typhoon 9200 (GE Healthcare) (Table 2).
Oligo rC25-Rho Binding Assays
Affinity (Km) of rC25 for the WT and mutant Rho proteins
was estimated from the extent of the oligo concentration-de-
pendent ATP hydrolysis using the double reciprocal plots
(Lineweaver-Burk plot) of the form: (1/V)  (Km  [S])/
(Vmax[S]), where,V and S are reaction velocity (nanomoles of
ATP hydrolyzed per g of Rho/min) and substrate con-
centrations, respectively. Plots were confined within the
dynamic range of the ATP hydrolysis. Experiments were per-
formed essentially following the methods measuring the
ATP hydrolysis rate as described above, except that oligo-
(dC)34 was added in the reactions to block interactions of
RNA at the PBS of Rho (Table 2).
Limited Proteolysis by Trypsin and V8 Proteases
To monitor the proteolytic cleavage products, WT and
mutant Rho proteinswere end-labeled by 32P at their respective
heart muscle kinase tag. This tag was introduced at the C ter-
minus of the Rho proteins. The heartmuscle kinase-taggedRho
proteins were radiolabeled with [-32P]ATP (3000 Ci/mmol)
using protein kinase A. 0.3 M of labeled Rho in T-buffer sup-
plemented with 1 mM ATP was subjected to proteolytic diges-
tion with 0.05 g of trypsin for the indicated time period at
TABLE 2
Properties of the primary and secondary RNA binding sites of the Rho* mutants
WT and Rho*
mutants
Dissociation constants for
poly(dC)34 (Kd)a
Km for rC
25 oligob
ATPase activity on
tR1 RNAc
M nmol of ATP/min/g of Rho
WT Rho 9.7	 2.0 467.6	 13 1.2	 0.06
P235H Rho 6.1	 0.3 26.7	 3 4.2	 0.2
R221C Rho 8.4	 2 32.8	 5 5.3	 0.5
I168V Rho 11.7	 1.5 52.3	 19 2.7	 0.4
R221A Rho 11	 0.7 62.5	 6 9.2	 0.8
a Dissociation constants (Kd) were calculated by fitting the binding isotherms to hyperbolic equation that is obtained from the plots of fluorescence intensities of fluorescein-
(dC)34 oligonucleotide at 520 nm upon addition of WT and Rho* mutants. Error bars were obtained from three independent measurements.
b Km was calculated from Lineweaver-Burk plot of the form, (1/V) (Km [S])/(Vmax[S]), where, V and S are reaction velocity (nanomoles of ATP hydrolyzed/g of Rho/
min) and substrate concentrations, respectively. Intercept on the x axis gave the measure of Km. Errors were obtained from three measurements.
c Rates of ATP hydrolysis were calculated from the time-course of ATP hydrolysis by WT and different Rho* mutant using TR1 RNA as an inducer. Release of Pi from
[32P]ATP was analyzed on the TLC plates. Error bars were obtained from three measurements.
NusG-mediated Regulation of Transciption Termination
OCOTBER 21, 2016•VOLUME 291•NUMBER 43 JOURNAL OF BIOLOGICAL CHEMISTRY 22401
 by guest on M
ay 28, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
37 °C. The reactions were stopped by SDS-loading dyes and
samples were heated to 95 °C for 3 min before loading onto a
12–16% gradient SDS-PAGE. For V8 digestion, 0.3 M of
labeled Rho were incubated with increasing concentrations of
V8 protease in the T-buffer supplemented with 1 mM ATP for
15 s at 37 °C. Molecular weight markers of end-labeled Rho
were generated by cyanogen bromide (CNBr, methionine-spe-
cific), Lys-C and submaxillary protease (Arg-C) mediated
cleavages following standard protocols. Gels were exposed
overnight to a phosphorimager screen and were scanned using
PhosphorImager Typhoon 9200 and analyzed by ImageQuant
software (Fig. 5, A–C).
Fluorescence Spectroscopy
Tb-GTP Quenching—The fluorescence quenching experi-
ments for studying the accessibility of the ATP binding pocket
in WT and different Rho mutants were performed in buffer
containing 10mMTris-HCl (pH7.0) and 100mMKCl at 25 °C in
a Hitachi F7000 fluorescence spectrophotometer, under CAT
mode, with a PMT voltage of 700 V and scan speed of 240 nm.
GTP complexed with TbCl3, Tb-GTP (3:1; 300 M terbium
chloride and 100 M GTP), upon excitation at 295 nm yields
two emission peaks at 488 and 547 nm (28, 29). As Rho can also
utilize GTP, it can be assumed that Tb-GTP binds to the same
ATP binding pocket. The fluorescence intensity at 547 nm was
used to monitor the acrylamide quenching pattern. The
changes in fluorescence intensity (F0/F)547 nm was plotted
against increasing concentrations of acrylamide (Q). Due to the
presence of both static (KS) and dynamic quenching (KD), a
modifiedStern-Volmer equation: (F0/F)5471 (KDKS)[Q]
KDKS[Q]2, where, F0 and F are the initial and final fluorescence
intensities, respectively and [Q] is the concentration of acryl-
amide (Fig. 6C). Quenching constantKSV, which approximately
equals to the dynamic quenching, were calculated from the ini-
tial slopes of the curves.
Fluorscein-Cys Rho Quenching—Different single Cys deriva-
tives of Rho were at first labeled with fluorescein-5-
malemide essentially following the procedure described
earlier (19). Fluorescence quenching assays of the fluoresce-
in-labeled Rho proteins were performed using the neutral
quencher acrylamide. Quenching was done by adding
increasing concentrations of acrylamide (10–100mM) to 100
nM of labeled Rho in buffer containing 20 mM phosphate
buffer, 150 mM NaCl, 8 mM EDTA. The quenching of fluo-
rescence intensity was monitored at 520 nm. The change in
fluorescence intensity at 520 nmwas plotted against increas-
ing concentrations of acrylamide (Fig. 8, A–E). The quench-
ing constant was obtained in a similar manner as described
above for the Tb-GTP fluorescence.
Intermolecular Cys-Cys Formation Assays
A 10 mM stock of Cu-P was prepared by adding 1 l of 1 M
CuSO4 and 3 l of 1 M phenanthroline in 100 l. In each reac-
tion, 1 mM Cu-P was added to 1 g of Rho and incubated for 5
min in a buffer containing 25 mM HCl (pH 7), 50 mM KCl, and
100mMNaCl. To observe the products, reactionmixtures were
run on 12% SDS-PAGE and the gels were visualized by Coo-
massie Blue staining (Fig. 8F).
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